Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the safety and clinical trial protocol for its drug RP-A501, which is intended for the treatment of Danon disease [4][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who purchased Rocket securities between February 27, 2025, and May 26, 2025 [4]. - Allegations include that the defendants made false statements about the safety of RP-A501 and failed to disclose serious adverse events, including participant deaths during the clinical trial [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file their papers by August 11, 2025, with the understanding that participation as a lead plaintiff is not necessary to share in any potential recovery [6]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation, being recognized multiple times by The National Law Journal and The Legal 500 [7].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501, particularly concerning serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a serious adverse event, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading information about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing serious risks, including the death of participants [3]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without disclosing this critical update to shareholders [3]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event, including a participant's death, the stock price of Rocket Pharmaceuticals fell significantly [4]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced scrutiny for its handling of clinical trial protocols and communication with investors [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [7]. Group 3: Financial Impact - Following the announcement of a clinical hold by the FDA due to a serious adverse event, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6]. Group 4: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses to contact them directly to discuss their legal options [1][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the viability and efficacy of its RP-A501 drug, particularly in relation to its Phase 2 clinical trial for Danon disease [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Rocket Pharmaceuticals misrepresented the reliability of information regarding the projected timeline and safety of the RP-A501 trial, leading to a false sense of security among investors [2]. - Following the announcement of a Serious Adverse Event (SAE) involving a patient in the trial, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, reflecting a significant loss in market value [3]. Group 2: Company Background - Rocket Pharmaceuticals is described as a fully integrated, late-stage biotechnology company focused on developing gene therapies for rare and severe diseases, with a direct on-target mechanism of action and clear clinical endpoints [1].

NEW YORK, June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events (SAEs) [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to artificially inflated stock prices [5]. Group 2: Investor Actions - Investors who purchased securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

DISCLAIMER Various statements in this presentation concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Al ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the trial following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The class period for the lawsuit is from February 27, 2025, to May 26, 2025 [2]. - Allegations include that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - On May 27, 2025, Rocket announced a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a SAE, which ultimately resulted in death [2]. - Following this announcement, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 11, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Rocket Pharmaceuticals, Inc. for alleged misrepresentations regarding the safety and clinical trial protocol of its drug RP-A501, which is intended for treating Danon disease [1][3]. Group 1: Lawsuit Details - The lawsuit covers investors who purchased Rocket's securities between February 27, 2025, and May 26, 2025 [1]. - Defendants are accused of failing to disclose serious risks associated with the clinical trial, including Serious Adverse Events (SAEs) and participant deaths [3]. - The company allegedly modified the trial protocol to include a new immunomodulatory agent without informing shareholders [3]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by August 11, 2025 [4]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].